The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.

被引：0

作者：

Tougeron, David

Dahan, Laetitia

El Hajbi, Farid

Le Malicot, Karine

Evesque, Ludovic

Aparicio, Thomas

Bouche, Olivier

Bonichon-Lamichhane, Nathalie

Chibaudel, Benoist

Angelergues, Antoine

Bordere, Anais

Phelip, Jean-Marc

Mabro, May

Artru, Pascal

Louvet, Christophe

机构：

[1] Univ Poitiers Hosp, Gastroenterol Dept, Poitiers, France

[2] Univ Hosp Timone, Hepatogastroenterol & Oncol Dept, Marseille, France

[3] Ctr Oscar Lambret, Lille, France

[4] FFCD, Dijon, France

[5] INSERM, U1231, Dijon, France

[6] Ctr Antoine Lacassagne, Nice, France

[7] Hop St Louis, AP HP, Dept Gastroenterol, Paris, France

[8] Hop Robert Debr, Reims, France

[9] Clin Tivolis Ducos, Bordeaux, France

[10] Hosp Franco Britann, Fdn Cognacq Jay, Med Oncol, Levallois Perret, France

[11] Diaconesses Croix Simon Hosp, Paris, France

[12] St Malo Hosp, St Malo, France

[13] Univ Jean Monnet, St Etiennes, France

[14] Hop Foch, Suresnes, France

[15] Hop Prive Jean Mermoz, Lyon, France

[16] Inst Mutualiste Montsouris, Dept Med Oncol, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4036

引用

页数：1

共 50 条

[1] PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Tougeron, D.
Dahan, L.
El Hajbi, F.
Le Malicot, K.
Evesque, L.
Aparicio, T.
Bouche, O.
Lamichhane, N. Bonichon
Chibaudel, B.
Angelergues, A.
Bodere, A.
Phelip, J. M.
Mabro, M.
Artru, P.
Louvet, C.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1099 - S1100
[2] PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
Evrard, Camille
Louvet, Christophe
Hajbi, Farid E. L.
Fiore, Frederic D., I
Malicot, Karine L. E.
Aparicio, Thomas
Bouche, Olivier
Laurent-Puig, Pierre
Bibeau, Frederic
Lecomte, Thierry
Lievre, Astrid
Guimbaud, Rosine
Kim, Stefano
Zaanan, Aziz
Sokol, Harry
Chibaudel, Benoist
Desrame, Jerome
Pierre, Sabrina
Gonzalez, Daniel
Lepage, Come
Tougeron, David
DIGESTIVE AND LIVER DISEASE, 2021, 53 (04) : 420 - 426
[3] FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial
Tougeron, David
Dahan, Laetitia
Evesque, Ludovic
Le Malicot, Karine
El Hajbi, Farid
Aparicio, Thomas
Bouche, Olivier
Lamichhane, Nathalie Bonichon
Chibaudel, Benoist
Angelergues, Antoine
Bodere, Anais
Phelip, Jean-Marc
Mabro, May
Kaluzinski, Laure
Petorin, Caroline
Breysacher, Gilles
Rinaldi, Yves
Zaanan, Aziz
Smith, Denis
Gouttebel, Marie-Claude
Perret, Clement
Etchepare, Nicolas
Emile, Jean-Francois
Sanfourche, Ivan
Di Fiore, Frederic
Lepage, Come
Artru, Pascal
Louvet, Christophe
JAMA ONCOLOGY, 2024, 10 (06) : 709 - 717
[4] Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
Schlintl, Verena
Huemer, Florian
Greil, Richard
Weiss, Lukas
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (02) : 906 - 909
[5] FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: The RAMIRIS study.
Lorenzen, Sylvie
Thuss-Patience, Peter C.
Pauligk, Claudia
Goekkurt, Eray
Ettrich, Thomas Jens
Lordick, Florian
Reichardt, Peter
Stahl, Michael
Kopp, Hans-Georg
Hegewisch-Becker, Susanna
Reichart, Alexander
Alguel, Hana
Bichev, Dmitry
Kestler, Angelika
Hacker, Ulrich
Ziegenhagen, Nicolas Stephan
Mueller, Christian
Hermes, Barbara
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Phase II randomized study of Folfiri vs Folfiri plus Celecoxib in first line treatment of advanced colorectal cancer (ACRC)
Maiello, E.
Giuliani, F.
Romito, S.
Pezzella, G.
Mallamaci, R.
Di Renzo, G.
Di Bisceglie, M.
Gebbia, V.
Lopez, M.
Colucci, G.
ANNALS OF ONCOLOGY, 2005, 16 : 148 - 148
[7] Phase II randomized study of FOLFIRI vs FOLFIRI plus celecoxib in first line treatment of advanced colorectal cancer (ACRC).
Maiello, E
Giuliani, F
Romito, S
Pezzella, G
Mallamaci, R
Di Renzo, N
Di Bisceglie, M
Gebbia, V
Lopez, M
Colucci, G
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 284S - 284S
[8] FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for taxane-pretreated patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy - The phase II/III RAMIRIS study
Al-Batran, S-E.
Gotze, T. O.
Dechow, T.
Goekkurt, E.
Algul, H.
Decker, T.
Becker, S. Hegewisch
Hofheinz, R. D.
Mohler, M.
Stahl, M.
Thuss-Patience, P. C.
Herzer, S.
Pauligk, C.
Lorenzen, S.
ANNALS OF ONCOLOGY, 2020, 31 : S930 - S930
[9] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
Horita, Yosuke
Yamada, Yasuhide
Kato, Ken
Hirashima, Yoshinori
Akiyoshi, Kouhei
Nagashima, Kengo
Nakajima, Takako
Hamaguchi, Tetsuya
Shimada, Yasuhiro
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (06) : 604 - 609
[10] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
Yosuke Horita
Yasuhide Yamada
Ken Kato
Yoshinori Hirashima
Kouhei Akiyoshi
Kengo Nagashima
Takako Nakajima
Tetsuya Hamaguchi
Yasuhiro Shimada
International Journal of Clinical Oncology, 2012, 17 : 604 - 609

← 1 2 3 4 5 →